The Latest “Buzz on the Street” Show: Featuring Pressure Biosciences (OTCQB: PBIO) CBD News’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “CBD-Infused Beverages Achieve Quality and Clarity Breakthrough Utilizing Pressure BioSciences’ Ultra Shear Technology Platform”

Pressure BioSciences, Inc. (OTCQB: PBIO), today released a new, short video demonstrating the ability of the Company’s proprietary Ultra Shear Technology (UST™) platform to create water-soluble CBD oil that disperses instantly, resulting in improved dosing effectiveness, enhanced absorption, and more aesthetically-pleasing products when added to carbonated soft drinks, vitamin-infused sports drinks, and beer.

Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions.

The proliferation of cannabidiol, or CBD-based products, has exploded after U.S. President Donald Trump signed the Farm Bill in December 2018. Now, CBD products are appearing at supermarkets, health and wellness stores, smoke shops, coffee shops, and farmer’s markets around the country. Due to the rapid emergence of the industry, CBD products have expanded outwards from traditional oils and tinctures to shampoos, bath bombs, pet treats, and gummy bears. However, CBD still remains in a grey area due to its classifications as a cannabis derivative. On the other hand, CBD doesn’t cause any psychoactive effects like its THC counterpart, which is why CBD regulations are much more lenient than those focused on THC. CBD is primarily marketed as a health and therapeutic product, which ultimately led the U.S. Food and Drug Administration approval of Epidiolex, a CBD-based drug to treat epilepsy, as well as other CBD synthetic compounds. The biggest barrier to the CBD market is currently the lack of clinical trials and research. Regardless, studies conducted by medical institutions have already added enough credibility to CBD to cause a string of countries to legalize medical cannabis applications. The CBD industry has already made significant milestones within the past year and is expected to continually grow as research continues to develop. According to data compiled by Brightfield Group, the U.S. hemp CBD market is projected to reach USD 22 Billion by 2022, outpacing the rest of the cannabis market combined. 

The FDA has only approved Epidiolex for the treatment of epilepsy, however, studies have suggested that CBD is also effective in suppressing symptoms associated with cancer, chronic pain, Alzheimer’s, anxiety, depression, and many other medical conditions. CBD-based products are very versatile since they can potentially treat many conditions in different medical fields. Additionally, CBD requires a lower dosage and less frequent use when compared to traditional, medically-prescribed treatments such as opioids. Studies have shown that cannabis, in general, has significantly fewer side effects when compared to regulated and approved treatments within the market already. However, the FDA still requires much more research in order to approve or even possibly list cannabis-based medical treatments as a registered medicine. Regardless of the FDA’s decision, the market has already moved forward without the administration. “Literally overnight, you’re seeing CBD all around you and in everything,” said Troy Dayton, Chief Executive Officer of The ArcView Group, an Oakland, California-based cannabis investment and research firm. “This is a product that is going from relative obscurity to being on everyone’s mind: producers, consumers and especially entrepreneurs.”

For more information, please visit: Pressure Biosciences, Inc.

For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street

About Buzz on the Street: One of’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

[popuppress id=”206261″]

  1. Ron Goldberg 3 years ago

    CBD has none of the psychoactive effects and most benefits without clouding your mind. That is why they are in retailers like Walgreens now

    • Nico Padron 3 years ago

      With the passing of the 2018 Farm Bill – everyone and their brother is trying to cash in on CBD Oil sales. People are going out and buying CBD from drugs stores, online retailers, etc….

  2. Tammy Ravenwolf 3 years ago

    Cannabis Oil taken properly will help anxiety, too much will increase symptoms , it’s findin the right balance , energetically this plant is healin vice man made toxic drugs , they -Big Pharma make a fortune while peeps die , everyday

Leave a Comment